IQM-266
Based on 1 Customer Validation
IQM-266 is a Downstream Regulatory Element Antagonist Modulator (DREAM) ligand with a KD of 4.63 μM. IQM-266 inhibits the KV4.3/DREAM current in a concentration-, voltage-, and time-dependent-manner. IQM-266 also modulates A-type outward potassium currents (IA) from rat dorsal root ganglia (DRG) neurons. IQM-266 can be used for neurological disease research, such as Alzheimer’s disease and Huntington's disease (HD).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.42%
- CAS. Nr.: 1956337-58-8
- Formel: C25H19NO4
- Molecular Weight:397.42
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biologische Aktivität
Beschreibung
In Vitro
IQM-266 (0-100 μM) concentration-dependently inhibits Kv4.3/DREAM channels (IC50 = 8.6 μM) in CHO cells by slowing their activation and inactivation kinetics[1].
IQM-266 (0-100 μM) inhibits the maximum peak current and, to a lesser extent, the charge crossing the cell membrane during depolarization at ≥ 10 μM in CHO cells[1].
IQM-266 (3 μM) increases the charge through the cell membrane during the application of depolarizing pulses, and inhibits peak Kv4.3/DREAM current amplitude while slowing its inactivation in CHO cells[1].
IQM-266 (3-10 μM) slows the recovery process and increases closed-state inactivation of Kv4.3/DREAM channels in a concentration-dependent manner in CHO cells through its specific interaction with DREAM, which also underlies the observed increase in transmembrane charge[1].
IQM-266 (3-10 μM) dose-dependently reduces the peak amplitude of IA in rat DRG neurons[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS. Nr. 1956337-58-8
-
Appearance Solid
-
Molecular Weight 397.42
-
Formel C25H19NO4
-
Color White to light yellow
-
SMILES
O=C(NC1=CC(C=CC=C2)=C2C=C1C(O)=O)CC3=CC(OC4=CC=CC=C4)=CC=C3
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 100 mg/mL (251.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Research Protocol for Neurological Diseases
PINK1/Parkin-mediated mitophagy pathway is a mitochondrial quality-control signaling axis in which mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, activates Parkin recruitment and E3 ubiquitin ligase activity, promotes ubiquitination of outer mitochondrial membrane proteins, recruits selective autophagy adaptors, and drives lysosomal degradation of damaged mitochondria. In neurological disease research, this pathway is experimentally important because neurons, especially dopaminergic neurons, are highly dependent on mitochondrial integrity, and defective mitochondrial turnover can lead to mitochondrial dysfunction, oxidative stress, impaired neuronal survival, α-synuclein accumulation, and neuroinflammatory damage-associated signals. The genetic disease link is strongest in Parkinson’s disease because mutations in PRKN/parkin cause autosomal recessive juvenile parkinsonism, mutations in PINK1 cause hereditary early-onset Parkinson’s disease, and Drosophila studie
Reinheit & Dokumentation
-
Data Sheet (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5162 mL | 12.5811 mL | 25.1623 mL | 62.9057 mL |
| 5 mM | 0.5032 mL | 2.5162 mL | 5.0325 mL | 12.5811 mL | |
| 10 mM | 0.2516 mL | 1.2581 mL | 2.5162 mL | 6.2906 mL | |
| 15 mM | 0.1677 mL | 0.8387 mL | 1.6775 mL | 4.1937 mL | |
| 20 mM | 0.1258 mL | 0.6291 mL | 1.2581 mL | 3.1453 mL | |
| 25 mM | 0.1006 mL | 0.5032 mL | 1.0065 mL | 2.5162 mL | |
| 30 mM | 0.0839 mL | 0.4194 mL | 0.8387 mL | 2.0969 mL | |
| 40 mM | 0.0629 mL | 0.3145 mL | 0.6291 mL | 1.5726 mL | |
| 50 mM | 0.0503 mL | 0.2516 mL | 0.5032 mL | 1.2581 mL | |
| 60 mM | 0.0419 mL | 0.2097 mL | 0.4194 mL | 1.0484 mL | |
| 80 mM | 0.0315 mL | 0.1573 mL | 0.3145 mL | 0.7863 mL | |
| 100 mM | 0.0252 mL | 0.1258 mL | 0.2516 mL | 0.6291 mL |